{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.7","upperLimit":"31.8","value":"25.6"},{"groupId":"OG001","lowerLimit":"15.9","upperLimit":"27.0","value":"21.2"},{"groupId":"OG002","lowerLimit":"10.2","upperLimit":"20.7","value":"15.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"209"},{"groupId":"OG002","value":"207"}],"units":"Participants"}],"description":"Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"OG002","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"The PD-L1-High analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-High as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:\n\n≥25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control OR ≥25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control","reportingStatus":"POSTED","timeFrame":"Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).","title":"Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set","type":"SECONDARY","unitOfMeasure":"percentage of participants"}